ALX 5407
Alternative Names: ALX5407Latest Information Update: 22 Nov 2000
At a glance
- Originator NPS Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Glycine reuptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 22 Nov 2000 Discontinued-Preclinical for Schizophrenia in USA (Unknown route)
- 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
- 01 Jul 1998 Preclinical development for Schizophrenia in USA (Unknown route)